Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01543178 · ClinicalTrials.gov registry record · Phase 3
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Phase 3 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,583
- Enrollment target
NCT01543178 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 2,583 participants.
The verdict
NCT01543178, a Phase 3 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,583 participants
- Enrollment target
Study Summary
This study will evaluate the effectiveness and safety of repeat treatment with rifaximin 550 mg three times a day in patients with IBS with diarrhea who respond to initial treatment of rifaximin 550 mg three times a day.
Interventions
- DRUG open-label rifaximin
- DRUG double-blind placebo
- DRUG double-blind rifaximin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,583 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01543178
The ClinicalTrials.gov registry entry for NCT01543178 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,583 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which open-label rifaximin is the first listed.
NCT01543178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01543178 about?
NCT01543178 is a clinical study titled "Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study". This study will evaluate the effectiveness and safety of repeat treatment with rifaximin 550 mg three times a day in patients with IBS with diarrhea who respond to initial treatment of rifaximin 550 mg three times a day.
What is the current status of trial NCT01543178?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,583 participants. The study started on 2012-02. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01543178?
The interventions under investigation include: open-label rifaximin (DRUG), double-blind placebo (DRUG), double-blind rifaximin (DRUG).
Who is sponsoring clinical trial NCT01543178?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.